Clinical trial Recruiting at 1 site Observational Ages 6 to 15

Using DIMS Glasses to See if Myopia Progression Slows in Kids

Official title: Inhibition of Myopia Progression With Optical Devices

Run by Semmelweis University · NCT07698977 · Data updated 2026-11-12

This observational study tests whether wearing DIMS glasses in children and teens with myopia can slow progression, considering factors like outdoor time and family history.

Quick facts

Study typeObservational
Ages6 Years to 15 Years
SexAll
Enrollment50 (estimated)
SponsorSemmelweis University
Academic / other
Locations1 site (Budapest)
StatusRecruiting
StartedJune 2, 2026
Main results expectedMay 31, 2027
Study endsMay 31, 2027
Registry record updatedJuly 13, 2026
Trial IDNCT07698977 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal participants are 6–15 years old with myopia (−0.50 to −10.0 D) wearing myopia-control glasses and able to attend follow-up visits.

Probably not a fit

Children with very rapid progression, pathological myopia, or those unable to adhere to follow-up schedules may not experience benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a self-controlled observational study focusing on pediatric and adolescent myopia progression while wearing Defocus Incorporated Multiple Segments (DIMS) glasses during waking hours. The study collects data on refractive changes and environmental factors, including time spent outdoors and residence, over up to 24 weeks. Participants aged 6–15 with cycloplegic spherical equivalents between −0.50 and −10.0 diopters wear DIMS lenses to examine how progression changes with age and lifestyle. Diaries document subjective symptoms and environmental inputs to correlate with any changes in myopia progression. The primary aim is to observe real-world effects of these optical devices on rate of progression in this population.

Why it matters

Potential benefit: If successful, the approach could provide a practical option to slow myopia progression in children and adolescents.

How similar studies have gone: Previous work with DIMS lenses has shown potential slowing of myopia progression in similar pediatric populations, though this exact self-controlled observational design is comparatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* • Participants must be between 6 and 15 years of age at the start of myopia progression treatment

  * Caucasian ethnicity
  * Refractive error measured under cycloplegia, expressed as spherical equivalent: between -0.50 Dsph and -10.0 Dsph
  * Wearing myopia-control glasses while awake
  * Participation in follow-up examinations every 6 months

Exclusion Criteria:

* • Pathological myopia (e.g., myopia onset before age 6, Stickler syndrome)

  * Premature birth before the 32nd week of gestation
  * Previous eye-opening surgery (e.g., lens removal)
  * Traumatic eye injury
  * Known connective tissue disorder (e.g., Marfan syndrome)
  * Irregular or improper use of progressive-lens glasses
  * Failure to attend the follow-up examinations scheduled every 6 months

Where it's running

  • Semmelweis University Ophthalmology Department
    Budapest, Hungary
    Recruiting

Study contacts

  • Principal investigator: Zoltan Zs Nagy, Professor — Semmelweis University Ophthalmology Department
  • Study coordinator: Zoltan Zs Nagy, Professor
  • Email: szem.titkarsag@gmail.com
  • Phone: +3614591500

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

  • Optimizing light exposure to prevent and control myopia in children

    This study tests if changing classroom lighting to mimic sunlight or using a smartphone app to guide light exposure can help prevent and control myopia in primary school children.

    Recruiting at 5 sites National University of Singapore · Singapore and 4 other locations · NCT06631339

  • Where children look through their glasses

    This trial tests how children ages 7–14 look through a new spectacle lens design to see which parts of the lens they use during different tasks.

    Recruiting SightGlass Vision, Inc. · Bloomington, Indiana · NCT07229365

  • Children wearing spectacle lenses: mobility during everyday activities

    This test checks whether myopia-control spectacle lenses change how children aged 6–12 move and perform everyday mobility tasks compared with regular single-vision glasses.

    Recruiting SightGlass Vision, Inc. · Glendale, Arizona · NCT07229352

  • Evaluating a device for screening vision problems in young children

    This study is testing a new device to see if it can effectively find vision problems in children aged 3 to 8, whether they wear glasses or not.

    Recruiting Essilor International · Nancy, France and 1 other locations · NCT06882408

  • Testing low-dose atropine eye drops to slow down myopia in children

    This study is testing if low-dose atropine eye drops can help slow down worsening eyesight in children aged 6 to 12 who have myopia.

    Recruiting at 25 sites Phase 3 Oupushifang Pharmaceutical Technology Co., Ltd. · Hefei, Anhui and 24 other locations · NCT06708156

  • Controlling myopia in young children with a new type of glasses

    This study is testing a new type of glasses to see if they can help control the worsening of nearsightedness in children aged 6 to 8 years.

    Recruiting at 14 sites SightGlass Vision, Inc. · Oakland, California and 13 other locations · NCT06034327

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.